PubMed Health⌕ Search

Biomedical subjects

R B Stricker

Publications and source records attributed to R B Stricker.

At least 19 recordsLinked to original sources
PubMed1997

The Manchester seaman.

Explore the source record for details and available documents.

Acquired Immunodeficiency Syndrome↗
PubMed1996

Increase in lymphocyte subsets following treatment of HIV-associated neutropenia with granulocyte colony-stimulating factor.

Recombinant human granulocyte colony-stimulating factor (G-CSF) has been used to treat neutropenia in patients with cancer and HIV disease. Since lymphocyte counts have been reported to increase with G-CSF therapy, we studied the effect of G-CSF on lymphocyte subsets in HIV-infected patients. Six patients with HIV-associated neutropenia were treated with G-CSF and had significant increases in white blood cell counts. G-CSF induced a significant rise in total lymphocytes, total T-cells, CD8 T-cells, and natural killer cells. A smaller but statistically significant increase in CD4 T-cells and cytotoxic CD8 T-cells was also noted. We conclude that G-CSF has the ability to raise lymphocyte subset levels in patients with HIV disease. The potential immunologic benefit of G-CSF therapy merits further investigation.

CD4-Positive T-Lymphocytes↗
PubMed1995

AIDS research policy.

Explore the source record for details and available documents.

Acquired Immunodeficiency Syndrome↗
PubMed1995

Improved results of delayed-type hypersensitivity skin testing in HIV-infected patients treated with topical dinitrochlorobenzene.

BACKGROUND: Infection with HIV results in progressive deterioration of cell-mediated immunity, with consequent impairment of delayed-type hypersensitivity (DTH) skin reactivity. Topical dinitrochlorobenzene (DNCB) is thought to increase cellular immune function in HIV infection. OBJECTIVE: Our goal was to evaluate changes in DTH skin reactivity of HIV-infected patients who were given DNCB therapy. METHODS: DTH skin testing and lymphocyte subset analysis were performed in five HIV-infected patients before the start of DNCB treatment and after 3 months of therapy. Topical DNCB application was carried out by the patients according to a standardized protocol. RESULTS: DNCB therapy enhanced DTH skin test responses in four of five patients. Three patients who were anergic before the start of treatment reacted to skin test antigens while using DNCB. The skin test results did not correlate with lymphocyte subset changes. CONCLUSION: DNCB treatment improves DTH skin test responses in HIV-infected patients, indicating a positive effect on cellular immune function.

Administration, Cutaneous↗